[Bacteriological, pharmacokinetic and clinical studies of sulbactam/ampicillin in the pediatric field].
[Bacteriological, pharmacokinetic and clinical studies of sulbactam/ampicillin in the pediatric field].
复制标题
舒巴坦/氨苄西林在儿科领域的细菌学、药代动力学及临床研究
DOI：
--
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
Y. Kobayashi
中科院分区：
文献类型：
--
作者：
T. Haruta;S. Kuroki;K. Okura;N. Yoshioka;K. Yamaoka;H. Hashimoto;Y. Kobayashi
评价舒巴坦/氨苄西林（SBT/ABPC）治疗小儿感染的有效性。1. 20例感染患儿用SBT/ABPC治疗，剂量为27.8- 47.4mg/kg，静脉滴注，3 ~ 4次/d。除支原体肺炎2例（肺炎9例，尿路感染6例，扁桃体炎1例，上颌窦炎1例，骨髓炎1例）外，其余18例患者的临床疗效评定为优13例，良5例。没有失败的案例。2.对金黄色葡萄球菌1株、粪肠球菌3株、流感嗜血杆菌4株、副流感嗜血杆菌2株、大肠埃希菌5株、沙雷氏菌1株等16株菌的细菌学效力18例患者中13例患者分离的13株细菌被根除，1株细菌被减少，2株细菌未改变，根除率为81.3%。在根除的13株菌株中，3株为高产β-内酰胺酶菌株。3. 1例患者出现皮疹，7例患者出现嗜酸性粒细胞增多、GOT和GPT升高，但均不严重。4.在2例儿科患者中测定了静脉注射30 mg/kg剂量后的药物血液水平。静脉给药后30分钟，1例患者的SBT和ABPC血液水平分别为19.0和29.2 μ g/ml，另1例患者为21.0和31.6 μ g/ml，4小时时，1例患者的SBT和ABPC血液水平分别为0.48和0.62 μ g/ml，另1例患者为0.59和0.89 μ g/ml。2例患者中SBT的半衰期分别为0.67和0.70小时，ABPC的半衰期分别为0.64和0.69小时。（250字处删节）
The usefulness of sulbactam/ampicillin (SBT/ABPC) in the treatment of pediatric infections was evaluated. 1. Twenty pediatric patients with infection were treated with SBT/ABPC and an intravenous dosage of 27.8-47.4 mg/kg, 3 to 4 times a day. Clinical efficacies in 18 patients excluding 2 patients of Mycoplasma pneumonia (9 cases of pneumonia, 6 urinary tract infection, 1 tonsillitis, 1 maxillary sinusitis and 1 osteomyelitis) were judged to be excellent in 13 patients and good in 5. There was no case of failure. 2. Bacteriological efficacies against 16 strains (1 Staphylococcus aureus, 3 Enterococcus faecalis, 4 Haemophilus influenzae, 2 Haemophilus parainfluenzae, 5 Escherichia coli and 1 Serratia sp.) isolated from 13 of the 18 patients were rated as "eradicated" for 13 strains, "decreased" for 1 and "unchanged" for 2 with an eradication rate of 81.3%. Of 13 strains eradicated, 3 were those with high beta-lactamase productivity. 3. Rash as a side effect developed in 1 patient and eosinophilia and elevated GOT and GPT were observed in 7 patients but none of them were serious. 4. Blood levels of the drug following an intravenous dose of 30 mg/kg were determined in 2 pediatric patients. Blood levels of SBT and ABPC at 30 minutes after intravenous administration were 19.0 and 29.2 micrograms/ml in one patient and 21.0 and 31.6 micrograms/ml in another, respectively, and those at 4 hours were 0.48 and 0.62 microgram/ml in one patient and 0.59 and 0.89 microgram/ml in another, respectively. The half-lives of SBT were 0.67 and 0.70 hour and those of ABPC were 0.64 and 0.69 hour in the 2 patients, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)